FOLFOX2 in the Treatment of Advanced Colorectal Cancer: A Comparison Between Elderly and Middle Aged Patients

References

• Kim JH, Oh DY, Kim YJ, Han SW, Choi IS, Kim DW, et al. Reduced dose intensity Folfox-4 as first line palliative chemotherapy in elderly patients with advanced colorectal can-cer. J Kor Med Sci 2005; 20: 806–10.
   PubMed Web of Science ®Google Scholar
• Berardi R, Saladino T, Mari D, Silva RR, Scartozzi M, Verdecchia L, et al. Elderly patients with advanced colorectal can-cer: tolerability and activity of chemotherapy. Tumori 2005; 91: 463–66.
   PubMed Web of Science ®Google Scholar
• Aapro M, Extermann M, Repetto L. Evaluation of the eld-erly with cancer. Ann Oncol 2000; 11: 223–9.
   PubMed Web of Science ®Google Scholar
• Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 8: 2412-18.
   Google Scholar
• Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemother-apy. Cancer Chemother Pharmacol 1998; 42: 336–40.
   PubMed Web of Science ®Google Scholar
• Feliu J, Escudero P, Llosa F, Bolaiios M, Vicent JM, Yubero A, et al. Capecitabina as first-line treatment for patients older than 70 years with metastatic colorectal cancer: An onco-paz Cooperative group study. J Clin Oncol 2005; 23: 3104-11.
   Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, et al Pooled analysis of safety and effi-cacy of oxaliplatin plus fluorouracil/leucovorin administered bi-monthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085–91.
   PubMed Web of Science ®Google Scholar
• Comella P, Natale D, Farris A, Gambardella A, Maiorino L, Massidda B, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma - Final results of the Southern Italy Cooperative Oncology Group trial 0108. Cancer 2005; 104: 282–9.
   PubMed Web of Science ®Google Scholar
• Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Attain P, et al. Antitumoral activity of oxaliplatin in combination with 5-fluorouracil and the thymidase synthase in-hibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 1997; 8: 876–85.
   PubMed Web of Science ®Google Scholar
• Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxali-platin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053–71.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214–9.
   PubMed Web of Science ®Google Scholar
• Andre T, Louvet C, Raymond E, Tournigand C, de Gra-mont A. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer re-sistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1251–3.
   PubMed Web of Science ®Google Scholar
• Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for metasta-tic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560–8.
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL, et al. Oxaliplatin added to the simplified bi-monthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). Eur J Can-cer 1999; 35: 1338-42.
   Google Scholar
• WHO. WHO Handbook for reporting Results of Cancer Treatment. WHO offset publication No.48, Geneva: WHO 1979.
   Google Scholar
• Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–88.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Non-parametric estimation from in-complete observations. J Am Stat Assoc 1958; 53: 457–81.
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–70.
   PubMedGoogle Scholar
• Armitage P, Berry G. Statistical methods in medical re-search. Blackwell Sc. Publication, 1987.
   Google Scholar
• Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-flu-orouracil, folinic acid and oxaliplatin using an ambulatory multi-channel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992; 69: 893–900.
   Google Scholar
• Cascinu S, Del Ferro E, Catalano G. Toxicity and thera-peutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 1996; 19: 371–4.
   PubMed Web of Science ®Google Scholar
• Schrag D, Cramer LD, Bach PB, Begg CB. Age and ad-juvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Instit 2001; 93: 11:850–7.
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091–7.
   PubMed Web of Science ®Google Scholar
• Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Anton A, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study. J Clin Oncol 2005; 23: 3545-3551.
   Google Scholar
• Rosati G, Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorec-tal cancer. Tumori 2006; 92: 290–294.
   PubMed Web of Science ®Google Scholar
• Pasetto LM, Jirillo A, Iadicicco G, Rossi E, Paris MK, Mon-fardini S. Folfox versus Folfiri: A comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Res 2005; 25: 563–576.
   PubMed Web of Science ®Google Scholar
• Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcan-geli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity: analyses of a large scale phase II trial. Can-cer 1995; 75: 11–7.
   Google Scholar
• Zaniboni A, Labianca R, Marsoni S, Torn i V, Mosconi P, Grilli R, et al. GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma-long term results and evaluation of the indicators of health-related quality of life. Gruppo Italian° Valutazione Inter-venti in Oncologia. Studio Italian° Terapia Adiuvante Colon. Cancer 1998; 82: 2135–44.
   Google Scholar
• Ramsey SD, Andersen MR, Etzioni R, Moinpour C, Pea-cock S, Potosky A, Urban N. Quality of life in survivors of col-orectal carcinoma. Cancer 2000; 88: 1294–303.
   PubMed Web of Science ®Google Scholar
• Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluo-rouracil with a conventional bolus schedule in metastatic col-orectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425–32.
   PubMed Web of Science ®Google Scholar
• deBraud F, Munzone E, Note F, De Pas T, Biffi R, Brienza S, Aapro MS. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive dis-ease while on or after 5-fluorouracil. Am J Clin Oncol 1998; 21: 279–83.
   PubMed Web of Science ®Google Scholar
• Norum J. Oxaliplatin in colorectal cancer patients. Living in an arctic or subarctic area: significant cold-triggered dysesthe-sias and laryngeal reactions. J Chemother 2000; 12: 525–9.
   Google Scholar
• Haller DG. Safety of oxaliplatin in the treatment of col-orectal cancer. Oncology 2000; 14: 15–20.
   PubMed Web of Science ®Google Scholar
• Berretta M, Taibi R, Bearz A, La Mura N, Berretta S, TireIli U, Frustaci S. Dysphonia as an unusual toxic event of ox-aliplatin-based chemotherapy. J Chemother 2004; 16: 595–8.
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061–7.
   PubMed Web of Science ®Google Scholar